secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001140361-25-008557
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech announces FDA clearance of IND for Versamune MUC1 + PDS01ADC to treat metastatic colorectal cancer
--------------------------------------------------------------------------------

- FDA cleared IND for Versamune MUC1 (formerly PDS0103) + PDS01ADC to treat MUC1-positive unresectable metastatic colorectal carcinoma in failed prior treatment.
- Phase 1/2 trial will be led by the National Cancer Institute under a CRADA with PDS Biotech.
- MUC1 is over-expressed in colon, pancreatic, ovarian, breast, and NSCLC; study targets MSS mCRC, which accounts for 95% of mCRC patients.
- U.S. Patent #12,201,685 covers methods of using Versamune platform and immunocytokines including PDS01ADC.
- Company's primary focus remains on VERSATILE-003 Phase 3 trial in HPV16-positive head and neck squamous cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125008557/0001140361-25-008557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125008557/ef20045415_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-008557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer